This site is intended for healthcare professionals

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Activity
    • Actinic keratoses ..
    • Superficial actini..
    • Field damage in pa..
    • Businessman with s..
  • Post-Test
  • Evaluation
  • Claim Credit
Case studies - Non-hyperkeratotic, non-hypertrophic actinic keratosis

Case studies - Non-hyperkeratotic, non-hypertrophic actinic keratosis

Format

Knowledge

Published

November 24, 2016

Updated

November 24, 2016
Add to Queue


Programme Description

This activity looks at three patient case studies outlining the management of non-hyperkeratotic, non-hypertrophic actinic keratosis (AK), with a focus on ingenol mebutate gel. Ingenol mebutate gel is indicated for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults.

Educational Objectives

  • Describe how AK can present and how to distinguish AKs from inflammatory lesions of eczema or psoriasis
  • Recall that treatment for field change should be targeted at the wider area rather than the individual lesions
  • Review when ingenol mebutate gel would be a suitable management option for a patient with AK
  • Credit

    1.50

    Type

    Learning Credit(s)

    Disclosure

    Initiated, funded and reviewed by LEO Pharma and published by MIMS.
    Date of Preparation: October 2016; UK MAT-04102

    This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Any adverse events must be reported to LEO Pharma.

    Faculty

    Activity authors
  • Dr Chris Bower, Consultant Dermatologist at the Royal Devon and Exeter NHS Trust Hospital
  • Dr Caroline Morgan, Consultant Dermatologist and Lead Clinician for skin cancer at Poole Hospital NHS Foundation Trust
  • Dr Irshad Zaki, Consultant Dermatologist and Clinical Director at Heart of England NHS Foundation Trust

    Exam author
    Haymarket Medical
  • Instructions

    This is an industry-supported learning activity provided by MIMS Learning, featuring learning material and a test. Completing the test enables you to claim 1.5 learning credits (90 minutes learning). This credit award is recommended by MIMS Learning based on completing the activity and reflecting on what you have learned. If you spend less time on the activity we recommend claiming fewer credits.

    Please proceed with the activity until you have successfully answered all the test questions and completed your evaluation. You will then receive your MIMS Learning CPD certificate, which will be added to your CPD organiser for access at any time. This activity is offered at no cost.

    SYSTEM REQUIREMENTS

    Hardware and Software Requirements
    • A computer with an internet connection
    • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
    • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
    Add to Queue


    Prescribing information for Picato® 150 micrograms/gram (mcg/g) and 500 micrograms/gram (mcg/g) gel (ingenol mebutate) can be found here (PDF 42KB). Picato is indicated for cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults.